全球首创，为婴幼儿秋季腹泻防控提供中国方案

Core Viewpoint - The newly launched oral six-valent rotavirus vaccine developed by Wuhan Institute of Biological Products is the first of its kind globally, offering higher safety and efficacy, and is expected to be available for vaccination by the end of December [1][2]. Group 1: Vaccine Development and Features - The six-valent rotavirus vaccine took 18 years from research to production and is designed to prevent severe rotavirus diarrhea caused by six serotypes: G1, G2, G3, G4, G8, and G9 [1]. - This vaccine fills the gap in protection against the G8 strain, which has been prevalent in Asia, and provides a solution for global infant diarrhea prevention [1]. - The vaccine has an annual production capacity of 24 million doses, sufficient to meet the needs of infants in China [2]. Group 2: Clinical Efficacy - Phase III clinical trials involving 6,400 participants demonstrated a protection efficacy of 85.72% against severe rotavirus gastroenteritis [2]. - The vaccine shows a 100% efficacy rate against severe diarrhea caused by the G8 strain, significantly reducing the risk of severe cases and hospitalizations in infants [2]. - It is expected that after completing the vaccination schedule, the incidence of severe rotavirus diarrhea in children under five years old in China could decrease by over 80% [2]. Group 3: Vaccination Recommendations - The vaccine is recommended for infants aged 6 weeks to 3 years, with the vaccination process requiring three oral doses to be completed by 36 weeks of age [2]. - Despite being a voluntary Category 2 vaccine, it is emphasized as the most effective method for preventing rotavirus diarrhea, and early vaccination is encouraged [2].